A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated nonsmall-cell lung cancer

Alexander I. Spira, Nicholas O. Iannotti, Michael A. Savin, Marcus Neubauer, Nashat Y. Gabrail, Ronald H. Yanagihara, Edith A. Zang, Patricia E. Cole, Dale Shuster, Asha Das

Research output: Contribution to journal › Article › peer-review